WHO ICTRP trial
Study of the precision treatment of relapse/refractory diffuse large B cell…
ChiCTR2000036106 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000036106 |
|---|---|
| Public title | Study of the precision treatment of relapse/refractory diffuse large B cell lymphoma based on the NGS molecular classification |
| Scientific title | The establishment of a new technology for precise molecular classification of DLBCL and its translational application in the treatment of relapsed/refractory lymphoma |
| Primary sponsor | Fudan University Shanghai Cancer Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | DLBCL |
| Interventions | Group A:BTK inhibitor immunomodulator;Group B:BTK inhibitor;Group C:Immune checkpoint inhibitor;Group D:Selective targeted therapy |
| Registration date | Aug 21, 2020 |
| Target size | Group A:50;Group B:50;Group C:50;Group D:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: